

SPANISH HOSTING OFFERS - IF 2019

EURAXESS

TITLE

Marie Curie Post Doc position in Instituto de Investigación Biomédica de Málaga (IBIMA) :
Expression of Interest for Hosting a Marie Curie Fellowship

HOSTING SUMMARY

The group “Definition of phenotypes and molecular basis of hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Mechanisms involved and associated genetic factors” leading by Dr. José Antonio Cornejo-García at the Instituto de Investigación Biomédica de Málaga (IBIMA) in Málaga (Spain) is interested in hosting a Marie Curie Fellowship. One **Marie Skłodowska-Curie projects** is offered to be supervised by Dr. Cornejo-García.

Dr. / Prof Cornejo-García has a large trajectory of scientific excellence in the field of DHRs. Since 2012, he has been granted with uninterrupted funding, obtaining 4 projects as PI and collaborated in 16. He has published more than 60 peer-reviewed JCR-indexed articles, and he has been invited to participate in the peer-reviewed process for more than 15 JCR-indexed specialized journals. Currently he is supervising 2 PhD in the field of NSAIDs hypersensitivity. He is also member of the expert panel of the Andalusian Health Agency (Spain), the Spanish Agency of Scientific Evaluation (ANEP), and the European Commission (Expert number: EX20180335645). He has ongoing research collaboration with national and international research groups (Prof. Jean-Louis Guéant, INSERM-954, University of Lorena, France; Dr. Michael Lee, Geisinger Health System Scranton, Pennsylvania, USA; Prof. Marek Sanak, Department of Medicine, Jagiellonian University Medical College, Krakow, Poland; Dr. Carlos Flores, GD-ITER, Santa Cruz de Tenerife, Spain; Dr. Dolores Pérez-Sala, Biological Research Center, Madrid, Spain; among others).

Among his most recent articles are:

- Perkins JR et al. Pharmacogenomics J 2018. DOI: 10.1038/s41397-018-0038-0.
- Jurado-Escobar R et al. J Investig Allergol Clin Immunol 2017. doi: 10.18176/jiaci.0199.
- Cornejo-García JA et al. Pharmacogenomics J 2016. doi: 10.1038/tpj.2015.24.
- Perkins JR et al. Trends Pharmacol Sci 2015. doi: 10.1016/j.tips.2014.12.003.
- Guéant JL et al. J Allergy Clin Immunol 2015. doi: 10.1016/j.jaci.2014.07.047.
- Cornejo-García JA et al. Pharmacogenomics 2013. doi: 10.2217/pgs.13.166.

Outstanding contributions:

- Torres MJ et al. Clin Exp Allergy 2004. doi: 10.1111/j.1365-2222.2004.02110.x. 126 citations.
- Doña I et al. Clin Exp Allergy 2011. doi: 10.1111%2Fj.1365-2222.2010.03651.x. 120 citations.
- Padial A et al. Clin Exp Allergy 2008. doi: 10.1111/j.1365-2222.2008.02961.x. 73 citations.

HOSTING DETAILS

Description of the center: The Biomedical Research Institute of Málaga, IBIMA, is a space for multidisciplinary biomedical research that gathers the resources, skills and expertise of the main public University Hospitals, Primary Care Centres and the University of Málaga to constitute a powerful combine (www.ibima.eu/en).

IBIMA fosters translational research to accelerate the transference of the scientific breakthroughs into the prevention, diagnosis and treatment of Health Care.

IBIMA has been accredited as a Health Research Institute since January 15th 2015 by the National Health Institute Carlos III, on the basis of the Spanish Royal Decree 339/2004 of February 27th. It has a workforce of 853 people, of which 705 are researchers (56% of them having healthcare activity), 114 are technicians and 34 are managers, clustered in 44 consolidated, 4 emergent and 7 associated groups.

The Málaga Health Research Institute performs its research activities within the scope of the Andalusian Health System (SAS). The SAS is an autonomous body attached to the Ministry of Health of the Government of Andalusia, in the South of Spain. Its mission is to provide public, quality health care to the citizens of Andalusia seeking efficiency and optimum use of resources. At Málaga province, the SAS provides care to a population of 1.600.000 habitants coordinating the services of 2 University Hospitals and 48 Primary Care Centres in the city of Málaga together with those located throughout the rural territory of the province (4 Hospitals and 107 Primary Care Centres).

The IBIMA Strategic Plan_2018-2022 defines the evolution of the Institute taking into account the European, national and regional research policies, welcoming the collaboration with private entities and analyzing the province health indicators to establish the course of actions to become the scientific and technological reference for the citizens of Málaga and of the international community.

The backbone of the IBIMA organization has been the prioritization of the lines of research pursuing the greatest impact on the health of the citizens of the Málaga province. The Institute is structured around 4 Priority and 2 transversal Research Areas, where the Research Groups, the Common Research Facilities and the Research Support Units are coordinated for the execution and the management of the research. The IBIMA Research areas are:

- 1 Cardiovascular diseases, obesity and diabetes. Environmental determinants and lifestyle
 - 2 Oncology and Hematology
 - 3 Neurosciences, Chronicity, Aging and Health in vulnerable populations
 4. Autoimmune, infectious diseases, inflammation and allergy.
- Trasnversal 1. IBIMA Rare: Rare diseases
Transversal 2. IBIMA Tech: Technology Area in Health and Innovation

IBIMA Common Research Facilities (ECAI) are:

- | | |
|---------------------------|---|
| 1. Clinical studies | 6. Microscopy |
| 2. Biobank | 7. Biología celular (citometría y cultivos) |
| 3. Bioinformatics | 8. Cell production and GMP rooms |
| 4. Animal experimentation | 9. Proteomics |
| 5. Genomics | 10. Methodological and statistical advice |

IBIMA Research Support Units (UAI) are:

1. Quality, monitoring and evaluation
2. Project management
3. International Projects
4. Innovation and technology transfer

In July 2017, the European Commission awarded IBIMA_FIMABIS the HRS4R Seal in recognition of the commitment acquired in implementing the principles of the "European Charter of Researcher and Code of Conduct in the Recruitment of Researchers" through its HRS4R strategy Implementation Plan

IBIMA defines in its Training Plan 2018_2022 the aims and objectives regarding the training of IBIMA staff providing seminars, courses and events designed to foster high-quality scientific and technical training. IBIMA collaborates with the Málaga University Post-graduate Doctoral Life Science Programmes and Masters.

Regarding the research funding managing, justification and auditing FIMABIS provides IBIMA with management resources and services that are independent of the governing structures of IBIMA's partners that conforms the Institute, the Andalusian Health System (SAS) and the University of Málaga. This allows an efficient economic and administrative management that complies with the national, regional and international governmental-public and private funding agencies normative.

Description of the group:

This is a multidisciplinary group, which includes clinical and basic researchers, as well as lab technicians and nurses. We focus on the deep characterization of phenotypes induced by drug hypersensitivity, including both allergic and non-allergic reactions. Such characterization means the definition of clinical entities and the elucidation of molecular underlying mechanisms, including genetic influence.

Description of the project/projects:

Objective: To evaluate the participation on non-immunological mechanisms in different phenotypes of hypersensitivity to non-steroidal anti-inflammatory drugs.

Description Principal Investigator (*education, research experience, publications, projects, [ORCID ID](#), Researcher ID or other, etc.*)

Education: PhD.

Research experience of more than 15 years.

64 publications in peer reviewed journals.

4 research projects as PI. Collaborator in more than 15 projects.

ORCID ID: 0000-0003-3465-8735

Supervisor Publications

>> Publications= 66

H Index=20

Patent=1

Grants=5

Supervisor International collaborations:

He has ongoing research collaboration with national and international research groups (Prof. Jean-Louis Guéant, INSERM-954, University of Lorena, France; Dr. Michael Lee, Geisinger Health System Scranton, Pennsylvania, USA; Prof. Marek Sanak, Department of Medicine, Jagiellonian University Medical College, Krakow, Poland; Dr. Carlos Flores, GD-ITER, Santa Cruz de Tenerife, Spain; Dr. Dolores Pérez-Sala, Biological Research Center, Madrid, Spain; among others).

Supervisor most relevant research projects grants:

Hypersensitivity to nonsteroidal anti-inflammatory drugs by cross-intolerance: phenotypes definition, natural history and mechanisms involved. Carlos III Health Institute, Spanish Ministry of Science, Innovation and Universities.

More information:

MSCA-IF-2019

Expressions of Interest for hosting MSCA fellows



- Number of positions available: 1
- Type of contract: Full time
- Status:
- Working hours (hour per week or free text): 25 h/w
- State / province: Malaga
- City: Malaga
- Postal code: 29009
- Street: Hospital Civil, Pza. Hospital Civil s/n, Pabellón 5, sótano
- Organisation: IBIMA
- Faculty / department: Research Laboratory
- Country: Spain
- City: Malaga
- State/province: Malaga
- Website: <http://www.ibima.eu/>
- Phone mobile phone: 600616673

APPLICATION DETAILS

- Envisaged job starting date: January 2020
- Application deadline: 30 June 2019
- How to apply: By email
- Application e-mail : josea.cornejo@gmail.com

REQUIRED EDUCATION LEVEL

- Required education level 1: Biologist, Chemist, Biochemist
- Degree: PhD
- Degree field: Biology, Genetics, Clinical research

REQUIRED EXPERIENCE LEVEL

- Main research field: Biochemistry, molecular biology
- Sub research field: Genetics
- Years of research experience: 2-5

REQUIRED LANGUAGES

- Language: english
- Language level: CEFR equivalent to B2

MSCA-IF-2019

Expressions of Interest for hosting MSCA fellows



ADDITIONAL REQUIREMENTS

- Skills: Team work, collaborative, participative
- Specific requirements:

At the deadline for the submission of proposals (**September, 11th 2019**), researchers:

- shall be in possession of a doctoral degree or have at least four years of full-time equivalent research experience.
- must not have resided or carried out their main activities in the country of Spain for more than 12 months in the 3 years immediately prior to the abovementioned deadline.